Skip to main content
Clinical Trials/NCT03897621
NCT03897621
Completed
Not Applicable

The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery Based on Rotational Thromboelastometry (ROTEM®).

Thomas Jefferson University1 site in 1 country50 target enrollmentMay 20, 2019

Overview

Phase
Not Applicable
Intervention
Tranexamic Acid
Conditions
Coagulation; Intravascular
Sponsor
Thomas Jefferson University
Enrollment
50
Locations
1
Primary Endpoint
Fibrinolysis
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Total hip arthroplasty (THA) is associated with blood loss ranging from 300 to 2000 mL. Tranexamic acid (TXA) is frequently administered prophylactically during this procedure to reduce blood loss by inhibiting fibrinolysis or by stopping naturally occurring clot resolution. TXA is employed currently based on a surgeon's preference. The objective of this study is to quantitate the degree of fibrinolysis using rotational thromboelastometry (ROTEM) and investigate the role of TXA prophylaxis on blood loss in patients undergoing THA in a double-blind fashion. Our hypothesis is that fibrinolysis is minimal at most and TXA prophylaxis is not necessary during THA. All patients, whether they receive TXA or normal saline, will not be at risk, as at this time no data exists to determine which approach is safer or more effective. This is the first study to compare TXA vs. placebo in a double-blinded, randomized controlled trial.

Detailed Description

Total hip arthroplasty (THA) is associated with moderate blood loss ranging from 300 to 2000 mL. Tranexamic acid (TXA) is frequently administered prophylactically during this procedure to reduce blood loss by inhibiting fibrinolysis. Most clinical studies reported potential benefit of the treatment demonstrated by less estimated blood loss (EBL), reduced hemoglobin/hematocrit (HH) change, and reduced transfused packed red blood cells (PRBC). However, bleeding complication may be affected more significantly by the degree of surgical trauma and comorbidity of patients than coagulation abnormality. Further, the frequency and severity of fibrinolysis during these procedures have not been well studied. Additionally, TXA administration may increase the tendency of postoperative venous thrombosis by inhibiting fibrinolysis in already prothrombotic patients. The objective of this study is to quantitate the degree of fibrinolysis using rotational thromboelastometry (ROTEM) and investigate the role of TXA prophylaxis on clinical outcome in patients undergoing THA in a double-blind fashion. Our hypothesis is that fibrinolysis is minimal at most and TXA prophylaxis is not necessary during primary THA.

Registry
clinicaltrials.gov
Start Date
May 20, 2019
End Date
December 20, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Uzung Yoon

Clinical Instructor

Thomas Jefferson University

Eligibility Criteria

Inclusion Criteria

  • The study population will include total of 200 adults (age range of 18 - 85 years) who are in the American Society of Anesthesiologists (ASA) Physical Status (PS) 1-
  • Inclusion criteria are patients undergoing unilateral, primary, total hip arthroplasty.

Exclusion Criteria

  • Exclusion criteria include patient's refusal, patients with history of significant coagulopathy or on anticoagulation therapy. Female patients who are pregnant or nursing will be excluded. In addition, patients with anemia (Hb \< 8 g/dL) or who received blood transfusion within one week before surgery will be excluded. Patient receiving subcutaneous heparin on the same day prior to surgery will be also excluded.

Arms & Interventions

tranexamic acid

Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language

Intervention: Tranexamic Acid

Normal saline

Patients undergoing unilateral, primary, total hip arthroplasty with English as their native language

Intervention: Placebo

Outcomes

Primary Outcomes

Fibrinolysis

Time Frame: one hour after the end of surgery

Fibrinolysis based on ROTEM parameter, defined as ML (maxium lysis) \>15%

Secondary Outcomes

  • Blood loss(during surgery (intraoperative))
  • blood transfusion(Intraoperative and up to 72-hour after surgery)
  • Hematoma(up to72-hour after surgery)
  • Thrombotic events (PE, DVT).(up to 72-hour after surgery)
  • pre- and postoperative hemoglobin level(up to 72-hour after surgery)
  • Wound infection(up to 72-hour after surgery)

Study Sites (1)

Loading locations...

Similar Trials